PEEL Therapeutics

PEEL Therapeutics is on a mission to transform the treatment landscape for cancer and inflammatory diseases. Their approach is unlike any other,leveraging insights from evolutionary biology to identify and develop novel drug candidates. PEEL's proprietary discovery engine, Darwin.AI™, analyzes 100 million years of evolutionary data on disease resistance, pinpointing vulnerabilities that traditional methods might miss. PEEL then prioritizes areas with limited or no existing treatment options, offering hope to patients facing significant clinical challenges. Their lead product, PEEL-224, is a nanocarrier linked to 4 small molecules derived from camptothecin, a natural compound found in the Chinese Happy Tree. It is engineered to avoid chemotherapy resistance. This compound is a clinical-stage drug candidate being developed for the treatment of advanced solid tumors. PEEL has a robust pipeline of promising therapies in various stages of development, targeting both cancer and inflammatory diseases.

Jobs: